Direct Oral Anticoagulants Are Comparable to Low Molecular Weight Heparin at Sustaining the Circulating Extracellular Vesicle and Inflammatory Profiles of Cancer Associated Thrombosis Patients: An Observational Pilot Study.

ABSTRACT:

Introduction

Cancer patients face a 4 to 7-fold higher risk of developing thrombotic events compared to individuals without cancer. This elevated risk is driven by the underlying tumour biology and the effects of cancer treatments, significantly increasing the mortality rates of these patients. While low molecular weight heparin (LMWH) is the gold standard anticoagulation, direct oral anticoagulants (DOACs) are emerging as effective alternatives. Recent clinical evidence indicates reduced recurrent VTE upon DOAC treatment compared to LMWH; however, there is limited understanding of the underlying mechanistic pathways. Of interest, extracellular vesicles (EVs), released from a multitude of cells including platelets and tumour cells, are known as potent intercellular communication me

SUBMITTER: Macleod H 

PROVIDER: S-EPMC12035765 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature